UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 13, 2008
______________
Stellar Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)
______________
| | |
Ontario, Canada | 0-31198 | Not Applicable |
(State or Other Jurisdiction | (Commission | (I.R.S. Employer |
of Incorporation) | File Number) | Identification No.) |
544 Egerton Street, London, Ontario, Canada, N5W 3Z8
(Address of Principal Executive Office) (Zip Code)
(519) 434-1540
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02
Regulation FD Disclosure
On November 13, 2008, Stellar Pharmaceuticals Inc. ("Stellar" or the “Company today announced that for the three month period ended September 30, 2008, total product revenues increased by 19.6% compared to the same period in 2007.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
| | |
Exhibit No. | | Description |
99.1 | | Stellar Pharmaceuticals Inc. Announces Product Revenue Increases for Both Domestic and International Markets |
| | |
